[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jacobio Pharmaceuticals Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":181},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,75,102,124,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642548","phase-1-study-of-jab-23e73-in-combination-with-chemotherapy-in-participants-with-metastatic-pdac-harboring-kras-gene-alterations-100642548",false,"NCT07640295","Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","A Multicenter, Phase Ib\u002FIII Study to Evaluate JAB-23E73 in Combination With Nab-Paclitaxel and Gemcitabine in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Harboring KRAS Gene Alterations","Inclusion Criteria:\n\n1.Written informed consent signed by the participant or the participant's legally authorized representative must be obtained prior to performing any study-related procedures. 2. Histologically or cytologically confirmed metastatic PDAC.\n\n3\\. No prior systemic antitumor therapy for advanced disease (treatment-naïve). 4. Presence of KRAS gene alterations: be enrolled upon approval by the sponsor).\n\n5\\. ECOG performance status score of 0 or 1. 6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Inability to swallow oral medications or the presence of gastrointestinal dysfunction or disease that may significantly alter drug absorption.\n2. A history of another malignancy within 2 years prior to the first dose, histologically distinct from the cancer under study, except for carcinoma in situ of the cervix, superficial non-invasive bladder cancer, or adequately treated stage I non-melanoma skin cancer.\n3. Prior treatment with KRAS G12C inhibitors, KRAS G12D inhibitors, pan-KRAS inhibitors, or other agents of the same class.\n4. Primary central nervous system (CNS) tumors.\n5. Women who are pregnant or breast-feeding.\n6. Participants who have progressive disease or recurrence during neoadjuvant or adjuvant treatment, or within 6 months after the last dose of medication.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.",[27],"Metastatic Pancreatic Ductal Adenocarcinoma",[29,30,31,32,33,34,35,36],"KRAS","KRAS mutation","KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A,","Pan-KRAS","Pancreatic ductal adenocarcinoma","KRAS-mutant tumor","Targeted Therapy","JAB-23E73","NOT_YET_RECRUITING","2026-06-08",{"date":40,"type":41},"2026-06-10","ACTUAL",{"date":43,"type":20},"2026-06-22",{"date":45,"type":20},"2030-12-31",{"name":47,"class":48},"Jacobio Pharmaceuticals Co., Ltd.","INDUSTRY",13,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100545764","phase-1-jab-30355-in-patients-with-advanced-solid-tumors-harboring-tp53-y220c-mutation-100545764","NCT06386146","JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","A Phase 1\u002F2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","Inclusion Criteria:\n\n* Written informed consent.\n* Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).\n* ECOG performance status score of 0 or 1.\n* Has been treated with at least one line of systemic therapy for that tumor type and stage.\n* Have documentation of confirmed TP53 Y220C mutation.\n* At least 1 measurable lesion per RECIST v1.1.\n* Adequate hematological, renal and hepatic function and appropriate coagulation condition.\n* Able to swallow and retain orally administered medication.\n\nExclusion Criteria:\n\n* Active brain or spinal metastases or primary CNS tumor.\n* Active infection requiring systemic treatment within 7 days.\n* Active HBV or HCV.\n* Any severe and\u002For uncontrolled medical conditions.\n* LVEF ≤50% assessed by ECHO or MUGA.\n* QTcF \\> 470 msec.",{"count":58,"type":20},144,[23,24],"This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.",[62],"Solid Tumors",[64],"TP53 Y220C reactivator; TP53 Y220C mutation; P53; Tumor protein p53; TP53; Advanced solid tumors; Ovarian Cancer; JAB-30355","RECRUITING","2026-05-20",{"date":68,"type":41},"2026-05-22",{"date":70,"type":41},"2024-07-24",{"date":72,"type":20},"2027-07",{"name":47,"class":48},15,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100589838","phase-1-a-phase-iiia-study-of-jab-23e73-in-patients-with-advanced-solid-tumors-harboring-kras-gene-alteration-100589838","NCT06959615","A Phase I\u002FIIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","A Multicenter, Open Phase I\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","Inclusion Criteria:\n\n1. Histological or cytologically proven diagnosis of a locally advanced, unresectable, and\u002For metastatic solid tumor cancer with evidence of KRAS gene alteration (including gene mutation and wild type amplification).\n2. Able to provide an archived tumor tissue sample or fresh biopsy sample.\n3. Life expectancy ≥3 months at the start of treatment.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. ≥1 measurable lesion per RECIST v1.1.\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Unable to swallow oral medications or with gastrointestinal dysfunction or gastrointestinal disease that significantly alters the absorption of medication.\n2. Previous treatment with rat sarcoma (RAS) targeting agents.\n3. Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.\n4. Impaired cardiovascular function or clinically significant cardiac disease.\n5. Mean QT interval corrected using Fridericia's formula (QTcF) \\>470 msec.\n6. Females who are pregnant or breastfeeding.",{"count":83,"type":20},334,[23,24],"This is a multicenter, open-label, phase I\u002FIIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.",[87],"Advanced Solid Tumor",[29,30,89,32,90,91,92,34,35,36],"KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A, KRAS G12D","NSCLC","Pancreas cancer","Colorectal cancer","2026-01-16",{"date":95,"type":41},"2026-01-20",{"date":97,"type":41},"2024-11-22",{"date":99,"type":20},"2027-08-31",{"name":47,"class":48},32,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100590910","phase-1-jab-23e73-in-adult-participants-with-advanced-solid-tumors-with-kras-alteration-100590910","NCT06973564","JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","A Phase 1\u002F2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration","Inclusion Criteria:\n\n* Written informed consent.\n* Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).\n* Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.\n* Patients must have KRAS alterations.\n* Participants are required to provide an archived tumor sample.\n* Patients with a life expectancy ≥3 months.\n* ECOG performance status score of 0 or 1.\n* Patients must have at least one measurable lesion as defined by RECIST v1.1.\n\nExclusion Criteria:\n\n* Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the absorption of the study drug.\n* Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, or pan\u002Fmulti-KRAS inhibitors.\n* Known serious allergy to JAB-23E73 or excipient.\n* Patients with primary central nervous system tumors.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures or medical intervention.\n* QT interval\\>470 msec.\n* LVEF ≤50% assessed by ECHO or MUGA.",{"count":110,"type":20},294,[23,24],"This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors",[114],"Advanced Solid Tumors",[29,30,89,32,35,90,91,92,34,36],"2026-01-14",{"date":93,"type":41},{"date":119,"type":41},"2025-05-29",{"date":121,"type":20},"2028-02",{"name":47,"class":48},4,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":143,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100415211","phase-1-a-first-in-human-jab-8263-in-adult-patients-with-advanced-tumors-100415211","NCT04686682","A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","A Phase I\u002FIIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Subjects must meet all the following criteria in order to be included in the research study:\n\n  1. Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF).\n  2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n  3. Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have a tumor for which no standard therapy(ies) exists.\n  4. Subjects with recurrent\u002Frefractory AML according to WHO 2016\n  5. Subjects with life expectancy ≥3 months.\n  6. Patients with solid tumor must have at least one measurable lesion as defined by RECIST v1.1.\n  7. Patients who have sufficient baseline organ function.\n\nExclusion Criteria:\n\n1. History (≤3 years) of cancer that is histologically distinct from the cancer under study.\n2. Known serious allergy to investigational drug or excipients\n3. Active brain or spinal metastases\n4. History of pericarditis or Grade ≥2 pericardial effusion\n5. History of interstitial lung disease.\n6. History of Grade ≥2 active infections within 2 weeks\n7. Known human immunodeficiency virus (HIV) infection\n8. Seropositive for hepatitis B virus (HBV)\n9. Seropositive for hepatitis C virus (HCV), or HCV-RNA viral levels are not detectable.\n10. Any severe and\u002For uncontrolled medical conditions\n11. History of myocardial infarction, unstable angina pectoris, coronary artery bypass graft, or cerebrovascular accident\n12. Impaired cardiac function or clinically significant cardiac diseases\n13. QTcF \\>470 msec at screening\n14. History of medically significant thromboembolic events or bleeding diathesis\n15. Unresolved Grade \\>1 toxicity\n16. History of malignant biliary obstruction\n17. Pregnant or breast-feeding",{"count":132,"type":20},152,[23,24],"This is a Phase 1\u002F2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.\n\nThese two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.",[90,136,137,138,139,140,141,142],"SCLC","CRPC","ESCC","Ovarian Carcinoma","AML","MF","Malignant Tumor",[144,145],"BET inhibitor","Bromodomain and Extra-terminal","2026-01-08",{"date":148,"type":41},"2026-01-09",{"date":150,"type":41},"2021-05-07",{"date":152,"type":20},"2028-07",{"name":47,"class":48},1,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":171,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100476939","phase-1-jab-2485-activity-in-adult-patients-with-advanced-solid-tumors-100476939","NCT05490472","JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","A Phase 1\u002F2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must be able to provide an archived tumor sample\n* Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor\n\n  * Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated\n* Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n* Must have at least 1 measurable lesion per RECIST v1.1\n* Must have adequate organ functions\n* Must be able to swallow and retain orally administered medication\n\nExclusion Criteria:\n\n* Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days\n* Active infection requiring systemic treatment within 7 days\n* Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV\n* Any severe and\u002For uncontrolled medical conditions\n* left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)\n* QT interval using Fridericia's formula (QTcF) interval \\>470 msec\n* Experiencing unresolved CTCAE 5.0 Grade \\>1 toxicities\n* Clinically significant eye disorders",{"count":163,"type":20},102,[23,24],"This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.",[62,167,168,169,170],"ER+ Breast Cancer","Triple Negative Breast Cancer, TNBC","ARID1A Gene Mutation","Small Cell Lung Cancer, SCLC",[172,169],"Aurora A inhibitor","2026-01-07",{"date":148,"type":41},{"date":176,"type":41},"2022-12-20",{"date":178,"type":20},"2027-08",{"name":47,"class":48},8,""]